Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Pancreatic cancer is notoriously deadly because it's usually caught too late — but two new blood tests are changing that story. PANXEON, a liquid biopsy combining three biomarkers and AI, showed strong sensitivity for early-stage disease and even precancerous lesions. Separately, a high-sensitivity ddPCR test detected KRAS-mutant tumor DNA far more often than standard methods, revealing a hidden group of high-risk patients who would otherwise be missed.
Pancreatic cancer kills so effectively because it hides — most cases aren't caught until the disease has already spread, leaving only a 13% five-year survival rate. Two new blood tests are now pushing back against that grim reality by detecting the disease earlier and more accurately than ever before.
The first, PANXEON, is an investigational liquid biopsy developed at City of Hope that analyzes three biomarkers — CA19-9, circulating microRNAs, and exosomal microRNAs — and uses AI to generate a composite risk score. In a multicenter study of 1,757 plasma samples, it achieved 86.8% sensitivity for early-stage (stage I/II) pancreatic ductal adenocarcinoma (PDAC) and even detected high-grade dysplasia — a precancerous condition — with 64.3% sensitivity, potentially opening a window for intervention before cancer fully develops.
The second test uses digital droplet PCR (ddPCR) to target the three most common KRAS mutations in pancreatic cancer. In a 106-patient prospective study, ddPCR detected KRAS-mutant circulating tumor DNA nearly four times more often than standard next-generation sequencing at diagnosis, and continued to outperform it after chemotherapy and surgery.
By the Numbers:
Why it matters: Both tests could fundamentally shift how pancreatic cancer is managed — catching it earlier when surgery is still possible, identifying high-risk patients who need closer monitoring, and guiding the use of emerging KRAS-targeted therapies like daraxonrasib. Larger validation studies are still needed, but the direction is clear: smarter, more sensitive liquid biopsies may finally give clinicians a stronger foothold against one of oncology's most challenging diseases.
